Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

CEO

Dr. Pierre Broqua Ph.D.

Employees

114

Country

ISIN

FR0013233012

Listings

0 Comments

Share your thoughts

FAQ

What is Inventiva stock price today?▼

The current price of IVEVF is $5.5 USD — it has increased by +0% in the past 24 hours. Watch Inventiva stock price performance more closely on the chart.

What is Inventiva stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Inventiva stocks are traded under the ticker IVEVF.

When is the next Inventiva earnings date?▼

Inventiva is going to release the next earnings report on September 25, 2026.

What is Inventiva revenue for the last year?▼

Inventiva revenue for the last year amounts to 2.31M USD.

What is Inventiva net income for the last year?▼

IVEVF net income for the last year is -28.37M USD.

How many employees does Inventiva have?▼

As of April 01, 2026, the company has 114 employees.

In which sector is Inventiva located?▼

Inventiva operates in the Health Care sector.

When did Inventiva complete a stock split?▼

Inventiva has not had any recent stock splits.

Where is Inventiva headquartered?▼

Inventiva is headquartered in Daix, FR.